DABRAFENIB FOR RESISTANT BRAF MUTATED MULTI-SYSTEM LANGERHANS CELL HISTIOCYTOSIS

被引：0
|
作者：
Hays, Julia Allyson [1 ,2 ]
机构：
[1] Childrens Mercy Hosp, Kansas City, MO 64108 USA
[2] Univ Missouri, Kansas City, MO 64110 USA
来源：
PEDIATRIC BLOOD & CANCER | 2023年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S19 / S20
页数：2
相关论文
共 50 条
  • [41] Importance of Multi-lineage Hematologic Involvement and Hypoalbuminemia at Diagnosis in Patients With "Risk-organ" Multi-system Langerhans Cell Histiocytosis
    Luis Braier, Jorge
    Rosso, Diego
    Latella, Antonio
    Chantada, Guillermo
    Ozuna, Blanca
    Ripoli, Mario
    Scopinaro, Marcelo
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2010, 32 (04) : E122 - E125
  • [42] Refractory Multisystem Langerhans Cell Histiocytosis with Marked and Durable Response to Dabrafenib
    Henry, Michael
    Williams, James A.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S13 - S13
  • [43] BRAF-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor
    Mastropolo, Rosemarie
    Close, Allison
    Allen, Steven W.
    McClain, Kenneth L.
    Maurer, Scott
    Picarsic, Jennifer
    BLOOD ADVANCES, 2019, 3 (12) : 1848 - 1853
  • [44] Coexisting BRAF-Mutated Langerhans Cell Histiocytosis and Primary Myelofibrosis with Shared JAK2 Mutation
    Holst, Johanne Marie
    Enemark, Marie Beck
    Plesner, Trine Lindhardt
    Pedersen, Martin Bjerregaard
    Ludvigsen, Maja
    d'Amore, Francesco
    CASE REPORTS IN HEMATOLOGY, 2021, 2021
  • [45] Specific polymorphisms of cytokine genes are associated with different risks to develop single-system or multi-system childhood Langerhans cell histiocytosis
    De Filippi, P
    Badulli, C
    Cuccia, M
    De Silvestri, A
    Dametto, E
    Pasi, A
    Garaventa, A
    del Prever, AB
    Todesco, A
    Trizzino, A
    Danesino, C
    Martinetti, M
    Aricò, M
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 132 (06) : 784 - 787
  • [46] A rare case of mortality with multi-system Generalised Indeterminate Cell Histiocytosis
    Morgan, Emma
    Yau, Benny
    Mortimore, Rohan
    Tang, Fiona
    Robertson, Ivan
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 97 - 98
  • [47] Dramatic Efficacy of Dabrafenib in Langerhans Cell Histiocytosis Harboring the BRAF V600E Mutation: Two Cases Report
    Luo, Danqing
    Shi, Xiaodong
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S22 - S22
  • [48] Dabrafenib, Alone or in Combination with Trametinib, in Pediatric Patients with BRAF V600 Mutation-Positive Langerhans Cell Histiocytosis
    Whitlock, James A.
    Geoerger, Birgit
    Roughton, Michael
    Choi, Jeea
    Osterloh, Lisa
    Russo, Mark
    Hargrave, Darren
    BLOOD, 2021, 138
  • [49] Outcome for Children with Multi-System Langerhans Cell Histiocytosis after Using a LCH II-Based Protocol in Shanghai, China
    Gao, Yi-Jin
    Wu, Fang-Fang
    Pan, Ci
    Chen, Jing
    Tang, Jing-Yan
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S20 - S20
  • [50] Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition
    Abla, Oussama
    Weitzman, Sheila
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2015, : 565 - 570
12345